Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,803 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02415621 | Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer | completed | Early Phase 1 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04305925 | Focal Laser Ablation of Prostate Cancer | completed | Early Phase 1 | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT01804712 | Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy | completed | Early Phase 1 | 8 | Christopher KaneOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT04457089 | Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer | completed | Early Phase 1 | 18 | Marc GoodmanOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT04051502 | ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study | completed | Early Phase 1 | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03734653 | Testosterone Therapy in Castration Resistant Prostate Cancer | completed | Early Phase 1 | 30 | University of Colorado, DenverOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT02111941 | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Early Phase 1 | 19 | Mayo ClinicOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT04049227 | Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer | completed | Early Phase 1 | 27 | Northwestern UniversityOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT03507608 | Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression | completed | Early Phase 1 | 25 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT06520449 | 68Ga-NTA-476 Imaging in Prostate Cancer(NTA-476) | completed | Early Phase 1 | 10 | Melbourne Theranostic Innovation CentreNETWORK | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04576871 | Re-treatment 225Ac-J591 for mCRPC | completed | Early Phase 1 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT05105087 | Gynecological Sentinel Lymph Nodes CEUS | completed | Early Phase 1 | 9 | Thomas Jefferson UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT04301414 | Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer(Neo-Red-P) | completed | Early Phase 1 | 26 | Columbia UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07069465 | Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging(PIONEER PSMA) | completed | Early Phase 1 | 10 | Urology Clinics of North TexasNETWORK | 1 | Jul 16, 2025 | clinicaltrials |
| NCT05320757 | Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients | completed | Early Phase 1 | 20 | The University of Hong KongOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT03987217 | Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients | completed | Early Phase 1 | 73 | University of UtahOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06959966 | Effects of Oligo-fucoidan on Leiomyoma Patients | completed | Early Phase 1 | 18 | Taipei Medical UniversityOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT03661437 | Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy | completed | Early Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT03768349 | PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer | completed | Early Phase 1 | 250 | Mayo ClinicOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT02420977 | Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer | completed | Early Phase 1 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT05110495 | IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy(WINGMEN) | completed | Early Phase 1 | 27 | University of OxfordOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06359821 | Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer | completed | Early Phase 1 | 4 | Sichuan UniversityOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT02042430 | Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Early Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 13, 2024 | clinicaltrials |
| NCT03232164 | PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer | completed | Early Phase 1 | 126 | University of Wisconsin, MadisonOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT03378297 | IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC(IMPACT) | completed | Early Phase 1 | 26 | Haukeland University HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT05518812 | Carboprost (Hemabate) for Fibroid Resection | completed | Early Phase 1 | 19 | Northwestern UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04067960 | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer | completed | Early Phase 1 | 197 | Mayo ClinicOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT03275857 | Cisplatin in Castration Resistant Prostate Cancer | completed | Early Phase 1 | 12 | University of RochesterOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT02113657 | T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer | completed | Early Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT03358563 | Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer | completed | Early Phase 1 | 30 | University of Wisconsin, MadisonOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT04726033 | 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)(CUPID) | completed | Early Phase 1 | 14 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 1, 2024 | clinicaltrials |
| NCT02728830 | A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers | completed | Early Phase 1 | 39 | AA SecordOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05773703 | Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer | completed | Early Phase 1 | 23 | Ratio Therapeutics, Inc.INDUSTRY | 1 | Dec 13, 2023 | clinicaltrials |
| NCT05725070 | Phase 0/1 Study of 212Pb-NG001 in mCRPC | completed | Early Phase 1 | 3 | ARTBIO Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT01253213 | BR55 in Prostate Cancer: an Exploratory Clinical Trial | completed | Early Phase 1 | 26 | Bracco Diagnostics, IncINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03927651 | ICG to Assess Ovarian Perfusion | completed | Early Phase 1 | 54 | Northwestern UniversityOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04158817 | 68Ga-THP-PSMA PET/CT in Prostate Cancer: Clinical Stage and Restage | completed | Early Phase 1 | 8 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04282967 | Streaming Web-based Exercise At Home: A Pilot Study | completed | Early Phase 1 | 12 | Celina ShirazipourOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT04976257 | Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion | completed | Early Phase 1 | 5 | Ryan Kohlbrenner, MDOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT04041128 | PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer | completed | Early Phase 1 | 14 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT02534376 | Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal | completed | Early Phase 1 | 63 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT02826382 | Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041 | completed | Early Phase 1 | 14 | Five Eleven Pharma, Inc.INDUSTRY | 1 | Jan 12, 2023 | clinicaltrials |
| NCT02013492 | Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery | completed | Early Phase 1 | 1 | William CarsonOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04266392 | Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand | completed | Early Phase 1 | 20 | Stony Brook UniversityOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT03028519 | Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer | completed | Early Phase 1 | 81 | University of OklahomaOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT03071328 | INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers | completed | Early Phase 1 | 10 | Duke UniversityOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT01979003 | Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion | completed | Early Phase 1 | 100 | University of ArkansasOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT02316834 | Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(POSITION) | completed | Early Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT02855697 | Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer(MOLTO) | completed | Early Phase 1 | 28 | The Christie NHS Foundation TrustOTHER | 1 | Feb 22, 2022 | clinicaltrials |
| NCT03018249 | Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer | completed | Early Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Nov 16, 2021 | clinicaltrials |
Data updated 13 days agoSource updated Sep 17, 2026source: clinicaltrials